Sofinnova Ventures, OrbiMed, Vivo Capital lead $60 mln funding in Ascendis Pharma
Sofinnova Ventures, OrbiMed and Vivo Capital have led a $60 million Series D funding in Ascendis Pharma, a biotechnology company. Other investors in the funding include Janus Capital Management, Venrock, RA Capital Management, Rock Springs Capital and Sectoral Asset Management. Ascendis Pharma's largest shareholder, Sofinnova Partners, also participated in the funding round. James Healy of Sofinnova Ventures, Jonathan Silverstein of OrbiMed and Albert Cha of Vivo Capital have joined the company's board of directors.
1 December 2014•4 mins read
